• Ovarian cancer mortality at 7 years post-randomization [ Designated as safety issue: No ]
  

• Health economics at 7 years post-randomization [ Designated as safety issue: No ]
  
• Quality of life at 7 years post-randomization [ Designated as safety issue: No ]
  
• Feasibility of screening at 7 years post-randomization [ Designated as safety issue: No ]
  
• Screen morbidity at 7 years post-randomization [ Designated as safety issue: No ]
  

OBJECTIVES:

• Determine the impact of preclinical detection of ovarian cancer by screening on ovarian cancer mortality in postmenopausal women.
• Determine the physical morbidity of ovarian cancer screening in this population.
• Determine the psychological consequences of screening results (true negative, true positive, false negative, and false positive) in this population.
• Compare the interventions that result from screening for ovarian cancer using CA 125 monitoring and ultrasound in this population.
• Compare the feasibility of population screening, in terms of compliance rates with annual screening for ovarian cancer with these strategies.
• Compare the performance of these screening strategies in this population.

OUTLINE: This is a randomized, multicenter study. Participants are randomized to 1 of 3 screening arms.

• Arm I: Participants do not undergo screening.
• Arm II: Participants undergo screening with an annual CA 125 level. Depending on the results of the test, some patients may undergo additional screening.
• Arm III: Participants undergo screening with an annual transvaginal or transabdominal ultrasound. Depending on the results of the test, some patients may undergo additional screening.

Participants in all arms complete a health questionnaire at 3.5 and 7 years after study entry.

PROJECTED ACCRUAL: A total of 200,000 participants (100,000 for arm I and 50,000 each for arms II and III) will be accrued for this study within 3 years.